A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood

Clinical and Experimental Immunology

Volumn 145, Issue 3, 2006, Pages 438-447

  Markovic, S N ^a,c   Nevala, W K ^a   Uhl, C B ^a   Celis, E ^b   McKean, D J ^a  

^a MAYO CLINIC   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c Cancer Vaccine Collaborative   (United States)

Author keywords

Artificial antigen presenting cells; Cytomegalovirus; Immunity; T cells; Tolerance

Indexed keywords

CANCER VACCINE; CD28 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; TETRAMER;

ANTIGEN PRESENTATION; ARTICLE; AUTOMATION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FLOW CYTOMETRY; FUNCTIONAL ASSESSMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; PEPTIDE ANALYSIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RELIABILITY; REPRODUCIBILITY; STANDARDIZATION;

ANTIGEN-PRESENTING CELLS; ANTIGENS, VIRAL; CANCER VACCINES; CELL CULTURE TECHNIQUES; CYTOMEGALOVIRUS; CYTOTOXICITY TESTS, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33747411420     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03157.x     Document Type: Article

References (16)

1. Nagorsen D, Marincola FM. How to analyze ex vivo T-cell responses in cancer patients. In Vivo 2002; 16:519-25.
2. Nagorsen D, Scheibenbogen C, Thiel E, Keilholz U. Immunological monitoring of cancer vaccine therapy. Expert Opin Biol Ther 2004; 4:1677-84.
3. Rosenberg SA, Sherry RM, Morton KE et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175:6169-76.
4. Oelke M, Maus MV, Didiano D, June CH, Mackensen A, Schneck JP. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat Med 2003; 9:619-24.
5. Thomas AK, Maus MV, Shalaby WS, June CH, Riley JL. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. Clin Immunol 2002; 105:259-72.
6. Dudley ME. To bead or not to bead. J Immunother 2003; 26:187-9.
7. Oelke M, Schneck JP. HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement. Clin Immunol 2004; 110:243-51.
8. Yan X, Johnson BD, Orentas RJ. Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. Immunology 2004; 112:105-16.
9. Salter RD, Howell DN, Cresswell P. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 1985; 21:235-46.
10. Monsurro V, Wang E, Yamano Y et al. Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 2004; 104:1970-8.
11. Walker EB, Disis ML. Monitoring immune responses in cancer patients receiving tumor vaccines. Int Rev Immunol 2003; 22:283-319.
12. Toes RE, van der Voort EI, Schoenberger SP et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 1998; 160:4449-56.
13. Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 1996; 156:3911-8.
14. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 1996; 93:7855-60.
15. Pinzon-Charry A, Maxwell T, Lopez JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol 2005; 83:451-61.
16. Pinzon-Charry A, Maxwell T, McGuckin MA, Schmidt C, Furnival C, Lopez JA. Spontaneous apoptosis of blood dendritic cells in patients with breast cancer. Breast Cancer Res 2005; 8:R5.